Gastrointestinal obstruction is a common problem in advanced malignant disease, but its management remains controversial. In those patients for whom surgery is not appropriate, medical intervention is the only remaining option. We present a series of 14 patients with intestinal obstruction who were managed with subcutaneous injections of octreotide, a somatostatin analogue which reduces the volume of gastrointestinal secretions. Good control of vomiting was achieved in 12 patients, and no major side effects were observed. Octreotide would appear to be a useful drug in this clinical situation.
Baines M., Oliver DJ, Carter RLMedical management of intestinal obstruction in patients with advanced malignant disease; a clinical and pathological study. Lancet1985; ii: 990-93.
2.
Chan A., Woodruff RKIntestinal obstruction in patients with widespread intraabdominal malignancy . J Pain Symptom Management1992; 7: 339-42.
3.
Gallick HL, Weaver DW, Sachs RJ et al. Chemistry and pharmacology of SMS 201-995, a long acting octapeptide analogue of somatostatin. Scand J Gastroenterol1986; 21 (suppl 119): 54-64.
4.
Ketcham AS, Hoy RC, Pilch YH, Morton DLDelayed intestinal obstruction following treatment for cancer. Cancer1970; 25: 406-10.
5.
Walsh Hpj, Schofield PFIs laparotomy for small bowel obstruction justified in patients with previously treated malignancy?Br J Surg1984; 71: 933-35.
6.
Philips Rks, Hittinger R., Fry JS, Fielding LPMalignant large bowel osbtruction. Br J Surg1985; 72: 296-302.
7.
Baines MJThe medical management of intestinal obstruction in advanced cancer patients . First congress of the European Association of Palliative Care. Paris: European Association of Palliative Care, 1990: 71-75.
8.
Ventafridda V., Ripamonti C., Caraceni A., Spoldi E., Messina L., De Conno F.The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori1990; 76: 389-93.
9.
Mercadante S. , Maddaloni S.Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Management1992; 7: 496-98.
10.
Regnard C., Comiskey M.Nausea and vomiting in advanced cancer - a flow diagram. Palliative Med1992;6:146-51.
11.
De Conno F., Caraceni A., Zecca E., Spoldi E., Ventafridda V.Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction . J Pain Symptom Management1991; 6: 484-86.
12.
Rhoo D., Rilev G., Waxman J.Control of emesis in bowel obstruction in terminally ill patients. Lancet1992;339:375-76.
13.
Mercadante S.The use of octreotide in bowel obstruction . Palliative Med1993; 7: 78.
14.
Mercadante S.Treatment of diarrhoea due to enterocolic fistula with octreotide in a terminal cancer patient. Palliative Med1992; 6: 257-59.
15.
Mulvihill S. , Pappas TD, Passaro E., Debas HTThe use of somatostatin and its analogs in the treatment of surgical disorders. Surgery1986; 100: 467-76.
16.
Mercadante S.Octreotide nel trattamento dei sintomi intestinali . 5° congresso nazionale Società italiana di cure palliative, Palermo, 13-15 November 1992: 122-25.
17.
Ples J., Bauer W., Briner U. et al. Chemistry and pharmacology of SMS 201-995, a long acting octapeptide analogue of somatostatin. Scand J Gastroenterol1986; 21 (suppl 119): 54-64.
18.
Kutz K., Nuesh E., Rosenthaler J.Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol1986; 21 (suppl 119): 65-72.
